

Press Release

BIONEER Corporation
www.bioneer.com

Bioneer inks \$9.2M licensing agreement with Yuhan for SAMiRNA Drug Development

September 24, 2015

BIONEER Corporation, a South Korea-based RNAi drug development company, announced today that it has entered into a strategic alliance with Yuhan, the Korea's largest pharmaceutical company, by signing a licensing agreement for Bioneer's SAMiRNA™ technologies for RNAi drug development. The agreement includes initial upfront and subsequent milestone payments to Bioneer totaling up to \$9.2 million plus running royalties. A separate licensing fee is structured when it is licensed out to another pharmaceutical company.

Under the agreement, Bioneer transfers the worldwide commercialization right for 3 targets and will supply Yuhan with drug candidate materials for pre-clinical and clinical trials, while Yuhan will proceed with pre-clinical and clinical development and then to commercialization. Earlier in May this year, Bioneer and Yuhan entered into a collaborative research contract to develop anticancer drug targeting immune checkpoints and their companion molecular diagnostics. Yuhan also announced separately yesterday that it decided on an equity investment of \$8.4M into Bioneer to expedite its research and development.

"Through this strategic alliance, Bioneer's SAMiRNA drug development programs will be enhanced utilizing Yuhan's abundant experiences and knowhow in pre-clinical and clinical stages. It will enable us to move forward to the next level in drug development." Han-Oh Park, Ph.D., founder and CEO of Bioneer, said in a statement.

Using SAMiRNA™ technology, Bioneer has been collaborating with Sanofi S.A. on therapeutics for liver cancer since 2012, and with Brown Medical School and Korea Institute of Toxicology on IPF/COPD target gene discovery and preclinical testing in a project funded through a \$1.4M grant awarded by the Korea Drug Development Fund. Commercialization rights for these R&D collaborations belong to Bioneer.

About SAMiRNA™ Technology

SAMiRNA™ (Self-Assembled Micelle inhibitory RNA) is a new paradigm of RNAi therapeutics with its single-molecular nanoparticles and lack of toxicity. It is a single chemical entity which spontaneously assembles into nanoparticles with a protective PEG coat. SAMiRNA™ nanoparticles can incorporate siRNA, miRNA or even antisense DNA, and are ideally sized for selective localization to either vascularized tumors or targeted tissues. Targeting is achieved through the incorporation of relevant moieties on the surface of SAMiRNA™. As a single solid-phase synthesized molecule, manufacturing and QC are far simpler than current lipid-based delivery methods. Bioneer's IP position associated with this technology is strong worldwide, and the company is very active in drug development, both autonomously and collaboratively.

About BIONEER Corporation

Bioneer was founded in 1992 as an R&D oriented biotechnology company in South Korea. As a vertically integrated corporation, Bioneer has core competencies in oligonucleotide based therapeutics using proprietary DNA/RNA synthesis chemistry, novel molecular biology enzymes and reagents, and instrumentation. Its innovative culture enables the company to provide comprehensive solutions to academia and the molecular diagnostic industry, while the novel technologies it develops become strong foundations for new drug development. The company has wholly owned subsidiaries in the U.S. and China. Bioneer (064550.KQ) is a public company being traded on KOSDAQ, a South Korea stock exchange market. <http://www.bioneer.com>

About Yuhan Corporation

Yuhan Corporation is a South Korea-based healthcare company founded in 1926. The company has positioned itself as the top pharmaceutical company in the market cap and in sales revenue in Korea. The core business consists of primary & specialty care, dietary supplement, household & animal care, and contract manufacturing of active pharmaceutical ingredients. It has a few subsidiaries and global presences in the forms of joint venture with Janssen(Belgium), the Clorox Company(USA), and Kimberly-Clark Corporation(USA). Yuhan (000100:KS) is a public company being traded on Korea Stock Exchange market. <http://eng.yuhan.co.kr>